RxDoctor Payments Data

Hal Crosswell, MD

Ophthalmology · Columbia, SCNPI 1639131295

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 36 payments — averaging $36.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$373
  • Rayner Intraocular Lenses Limited$217
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$125
  • Johnson & Johnson Surgical Vision, Inc.$105
  • Bausch & Lomb Americas Inc.$99
  • NEW World Medical,inc.$85
  • plus $321 from 10 others

What the payments were for

  • Food & beverage$1,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 40th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$394,235
Medicare patients
1,386
Services billed
3,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost112$44,769
RestasisCyclosporine24$30,073
Cyclosporine40$24,801
Fluorometholone185$13,355
RhopressaNetarsudil Mesylate14$8,370
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$6,800
Loteprednol Etabonate49$6,649
Latanoprost656$6,358
Travoprost41$6,101
VyzultaLatanoprostene Bunod20$5,011
Prednisolone Acetate129$4,912
ProlensaBromfenac Sodium11$3,677
CombiganBrimonidine Tartrate/Timolol17$3,477
Timolol Maleate401$3,301
Brimonidine Tartrate144$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$42$78,319153 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa$125$10,32660 claims
Aerie Pharmaceuticals, Inc.Rhopressa$31$8,37014 claims
Bausch & Lomb Americas Inc.Vyzulta$99$5,01120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →